David Elliott
About David Elliott
David Elliott is the Director of Corporate Accounts - Southeast at BeiGene, with over two decades of experience in the pharmaceutical and biotech industries, specializing in oncology and corporate account management.
Current Role at BeiGene
David Elliott is the Director of Corporate Accounts for the Southeast region at BeiGene. In this capacity, he is responsible for overseeing corporate account management and strategy development, focusing on expanding BeiGene's presence and partnerships within the Southeastern United States.
Previous Experience at Karyopharm Therapeutics and GSK
Before joining BeiGene, David Elliott worked at Karyopharm Therapeutics Inc. as the Director of Corporate Accounts - Trade, GPO, and Federal for 9 months in 2020-2021. He also served as Director of Strategic Accounts/Oncology Team Lead at GSK US from 2019 to 2020, where he managed strategic accounts within the oncology sector in the Southeast.
Roles at Eisai US
David Elliott held multiple positions at Eisai US, including Associate Director of Thought Leader Development for three months in 2019 and Senior Thought Leader Manager from 2018 to 2019. These roles involved developing relationships with key opinion leaders and managing strategic initiatives within the South Region.
Experience at Celgene and Novartis
David Elliott has substantial experience at Celgene, where he was a Senior Contracting Account Executive from 2012 to 2018, managing accounts across Florida, Georgia, Alabama, and Puerto Rico. Prior to that, he worked as a Hematology Oncology Specialist in West Palm Beach from 2008 to 2012. Elliott also worked at Novartis in various roles including Oncology Hematology Specialist, Cardiovascular Specialist, and Sales Specialist between 1999 and 2008.
Educational Background
David Elliott studied Biology and Marine Science at Eckerd College. His academic background has laid a foundation for his extensive career in the pharmaceutical and biotech industries, specializing in corporate account management and strategic account development within the oncology sector.